By 1992 Grotendorst, who had done work at the University of South Florida and is now at the University of Miami, concluded that it was CTGF, not TGF-beta, that triggers collagen production by binding to specific cell receptors.
Specific options include giving shareholders a binding veto on board pay, changing the make-up of pay committees and making compensation, including pay ratios, more transparent.